Endocrine Pharmacology USMLE Step 1 Practice Question
A 29-year-old woman with type 1 diabetes mellitus on mealtime insulin lispro presents with persistent postprandial glucose excursions peaking at 280 mg/dL despite carbohydrate counting. Vital signs: BP 118/76, HR 88, RR 16, temp 37°C, SpO2 98%. HbA1c is 8.2%, and fasting C-peptide is undetectable, confirming absent endogenous insulin secretion. Physical exam reveals no abdominal tenderness or distension. Her endocrinologist adds a subcutaneous amylin analog administered before meals that decreases glucagon secretion and slows gastric emptying. She denies nausea or gastrointestinal symptoms. Which of the following drugs was most likely added?
Answer choices
- ASemaglutide
- BMetformin
- CRepaglinide
- DPramlintideCorrect answer
- ESitagliptin
- FExenatide
See the full explanation
Get the correct-answer rationale, why each distractor is wrong, the underlying mechanism, and high-yield associations — plus adaptive practice that targets your weak areas — with a free MedBoardPRO account.